Candida auris cases rise as fungus spreads to 27 U.S. states

Candida auris, a drug-resistant yeast first identified in the United States in 2016, has been confirmed in 27 states, prompting heightened vigilance among health officials. The Centers for Disease Control and Prevention said more than 4,200 clinical cases were reported last year, and the agency expects the total to exceed that figure in 2026 after recording over 3,400 cases through July.

California leads with the highest number of infections, followed by Texas and Tennessee. C. auris can cause serious infections in patients with weakened immune systems, including wound, urinary tract and ear infections, and in severe instances may lead to sepsis. Some strains are resistant to standard antifungal drugs, complicating treatment.

The fungus spreads readily through contact with infected individuals, contaminated surfaces, and medical equipment such as central lines and breathing tubes. It can persist on surfaces for extended periods, raising concerns for hospitals and long-term care facilities.

"Early detection, appropriate medical care and adherence to infection-prevention protocols are essential to manage cases and limit transmission," a CDC spokesperson said.

While healthy individuals face low risk, patients with compromised immunity, prolonged hospital stays, or implanted medical devices remain most vulnerable. Experts advise continued surveillance and strict hygiene measures to control the outbreak.